Classic Hodgkin Lymphoma: The LYSA pragmatic guidelines

Cédric Rossi¹, Guillaume Manson², Amira Marouf³, Aurélie Cabannes-Hamy⁴, Emmanuelle Nicolas-Virelizier⁵, Marie Maerevoet⁶, Marion Alcantara⁷, Lysiane Molina⁸, Antony Ceraulo⁹, Marilyne Poirée¹⁰, Jean Galtier¹¹, Nadia Diop¹², Caroline Delette¹³, Amandine Segot¹⁴, Sydney Dubois¹⁵, Agathe Waultier¹⁶, Sophie Bernard¹⁷, Robin Noël¹⁸, Stéphanie Guidez¹⁹, Milena Kohn⁴, Sébastien Bailly¹², Hannah Moatti²⁰, Mohamed Touati²¹, Loïc Renaud²², Salim Kanoun²³, Anne-Ségolène Cottereau²⁴, Youlia Kirova²⁵, Karine Peignaux²⁶, Marie-Emilie Dourthe²⁷, Mathieu Simonin²⁸, Thierry Leblanc²⁹, Laurent Quéro³⁰, Daphné Krzisch³¹, Remy Duléry³², Adrien Grenier³³, Thomas Gastinne³⁴, Olivier Casasnovas³⁵, Andrea Gallamini³⁶, Marc André³⁷, Franck Morschhauser³⁸, Bénédicte Deau³, Luc-Mathieu Fornecker³⁹, Hervé Ghesquières⁴⁰

Affiliations

¹ Department of Hematology, Dijon Bourgogne University Hospital and INSERM UMR 1231, Dijon, France. Electronic address: cedric.rossi@chu-dijon.fr.
² Department of Hematology, university hospital of Rennes, Rennes, France.
³ Department of Hematology, Cochin Hospital, AP-HP, Paris, France; INSERM UMR 1163, Institut Imagine, Paris, France; Université de Paris, France, Institut Imagine, Paris, France.
⁴ Department of Hematology, CH de Versailles, Le Chesnay, France.
⁵ Department of Hematology, Leon Bérard Center, Lyon, France.
⁶ Institut Jules Bordet, Hôpital Universitaire de Bruxelles, Université Libre de Bruxelles, Belgium.
⁷ CellAction, Center for Cancer Immunotherapy, Institut Curie, Suresnes, France and Clinical Hematology Unit, Institut Curie, Saint-Cloud, France.
⁸ Department of Hematology, University Hospital Grenoble Alpes, Grenoble, France.
⁹ Department of Pediatric Oncology and Hematology, Institut d'Hématologie et d'Oncologie Pédiatrique (IHOPe), and University Lyon I, Lyon, France.
¹⁰ Department of Pediatric Hematology-Oncology, University Hospital Nice, Nice, France.
¹¹ Department of Hematology-Transplantation, Hôpital de Bordeaux, Bordeaux, France.
¹² Department of Hematology and cell therapy, CHU de Clermont-Ferrand, Clermont-Ferrand, France.
¹³ Department of Clinical Hematology, Amiens University Hospital, Amiens, France.
¹⁴ Department and Central Laboratory of Hematology, Lausanne University Hospital, Lausanne, Switzerland.
¹⁵ Department of Hematology, Centre Henri Becquerel, Rouen, France.
¹⁶ Department of Hematology, CHU de Nîmes, France.
¹⁷ Department of Hematology, Centre Hospitalier de la Côte Basque, Bayonne, France.
¹⁸ Department of Hematology, Institut Paoli-Calmettes, Marseille, France.
¹⁹ Department of Hematology, CHU de Poitiers, Poitiers, France.
²⁰ Department of Hematology, APHP, Saint-Louis Hospital, Paris, France.
²¹ Department of Clinical Hematology and Cellular Therapy, CHU Limoges, Limoges, France.
²² Department of Hematology, Gustave Roussy, Université Paris-Saclay, 94800 Villejuif, France.
²³ Department of Nuclear Medicine, Oncopole, Toulouse, France.
²⁴ Department of Nuclear Medicine, Cochin Hospital, AP-HP, University of Paris Cité, Paris, France.
²⁵ Department of Radiation Oncology, Institut Curie, 75005 Paris, France.
²⁶ Department of Radiotherapy, Centre Georges-François Leclerc, 21079 Dijon, France.
²⁷ Necker Children's Hospital, AP-HP, Paris, France.
²⁸ Department of Pediatric Hematology and Oncology, Armand Trousseau Hospital, APHP, Sorbonne Université, Paris, France.
²⁹ Department of Pediatric Immunology and Hematology and CRMR aplasies médullaires, Robert Debré Hospital, Groupe Hospitalier Universitaire, AP-HP-Paris Nord, Université de Paris Cité, Paris, France.
³⁰ INSERM U1160, Université Paris Cité, Paris, France; Department of Radiation Oncology, AP-HP Nord, Saint-Louis Hospital, Paris, France, Université Paris Cité, Paris, France.
³¹ Department of Hematology, APHP, Hospital Saint Louis, Paris, France.
³² Sorbonne University, Department of Clinical Hematology and Cellular Therapy, Saint-Antoine Hospital, AP-HP, INSERM UMRs 938, Paris, France.
³³ Sorbonne University, Department of Clinical Hematology Hôpital Pitié-Salpêtrière, AP-HP, Paris, France.
³⁴ Department of Hematology, Centre hospitalo-Universitaire, Nantes, France.
³⁵ Department of Hematology, Dijon Bourgogne University Hospital and INSERM UMR 1231, Dijon, France.
³⁶ Research and Clinical Innovation Department, Antoine Lacassagne Cancer Center, Nice, France.
³⁷ Department of Hematology, CHU UCL Namur, Yvoir, Belgium.
³⁸ Université de Lille, Centre Hospitalier Universitaire (CHU) Lille, ULR 7365 - GRITA - Groupe de Recherche sur les Formes Injectables et les Technologies Associées, Lille, France.
³⁹ Department of Hematology, Institut de Cancérologie Strasbourg Europe (ICANS), Strasbourg, France.
⁴⁰ Department of Hematology, Hospices Civils de Lyon, CHU Lyon-Sud, Pierre-Bénite, France.

PMID: 39509848
DOI: 10.1016/j.ejca.2024.115073

Free article

Review

Classic Hodgkin Lymphoma: The LYSA pragmatic guidelines

Cédric Rossi et al. Eur J Cancer. 2024 Dec.

Free article

. 2024 Dec:213:115073.

doi: 10.1016/j.ejca.2024.115073. Epub 2024 Oct 22.

Authors

Affiliations

¹ Department of Hematology, Dijon Bourgogne University Hospital and INSERM UMR 1231, Dijon, France. Electronic address: cedric.rossi@chu-dijon.fr.
² Department of Hematology, university hospital of Rennes, Rennes, France.
³ Department of Hematology, Cochin Hospital, AP-HP, Paris, France; INSERM UMR 1163, Institut Imagine, Paris, France; Université de Paris, France, Institut Imagine, Paris, France.
⁴ Department of Hematology, CH de Versailles, Le Chesnay, France.
⁵ Department of Hematology, Leon Bérard Center, Lyon, France.
⁶ Institut Jules Bordet, Hôpital Universitaire de Bruxelles, Université Libre de Bruxelles, Belgium.
⁷ CellAction, Center for Cancer Immunotherapy, Institut Curie, Suresnes, France and Clinical Hematology Unit, Institut Curie, Saint-Cloud, France.
⁸ Department of Hematology, University Hospital Grenoble Alpes, Grenoble, France.
⁹ Department of Pediatric Oncology and Hematology, Institut d'Hématologie et d'Oncologie Pédiatrique (IHOPe), and University Lyon I, Lyon, France.
¹⁰ Department of Pediatric Hematology-Oncology, University Hospital Nice, Nice, France.
¹¹ Department of Hematology-Transplantation, Hôpital de Bordeaux, Bordeaux, France.
¹² Department of Hematology and cell therapy, CHU de Clermont-Ferrand, Clermont-Ferrand, France.
¹³ Department of Clinical Hematology, Amiens University Hospital, Amiens, France.
¹⁴ Department and Central Laboratory of Hematology, Lausanne University Hospital, Lausanne, Switzerland.
¹⁵ Department of Hematology, Centre Henri Becquerel, Rouen, France.
¹⁶ Department of Hematology, CHU de Nîmes, France.
¹⁷ Department of Hematology, Centre Hospitalier de la Côte Basque, Bayonne, France.
¹⁸ Department of Hematology, Institut Paoli-Calmettes, Marseille, France.
¹⁹ Department of Hematology, CHU de Poitiers, Poitiers, France.
²⁰ Department of Hematology, APHP, Saint-Louis Hospital, Paris, France.
²¹ Department of Clinical Hematology and Cellular Therapy, CHU Limoges, Limoges, France.
²² Department of Hematology, Gustave Roussy, Université Paris-Saclay, 94800 Villejuif, France.
²³ Department of Nuclear Medicine, Oncopole, Toulouse, France.
²⁴ Department of Nuclear Medicine, Cochin Hospital, AP-HP, University of Paris Cité, Paris, France.
²⁵ Department of Radiation Oncology, Institut Curie, 75005 Paris, France.
²⁶ Department of Radiotherapy, Centre Georges-François Leclerc, 21079 Dijon, France.
²⁷ Necker Children's Hospital, AP-HP, Paris, France.
²⁸ Department of Pediatric Hematology and Oncology, Armand Trousseau Hospital, APHP, Sorbonne Université, Paris, France.
²⁹ Department of Pediatric Immunology and Hematology and CRMR aplasies médullaires, Robert Debré Hospital, Groupe Hospitalier Universitaire, AP-HP-Paris Nord, Université de Paris Cité, Paris, France.
³⁰ INSERM U1160, Université Paris Cité, Paris, France; Department of Radiation Oncology, AP-HP Nord, Saint-Louis Hospital, Paris, France, Université Paris Cité, Paris, France.
³¹ Department of Hematology, APHP, Hospital Saint Louis, Paris, France.
³² Sorbonne University, Department of Clinical Hematology and Cellular Therapy, Saint-Antoine Hospital, AP-HP, INSERM UMRs 938, Paris, France.
³³ Sorbonne University, Department of Clinical Hematology Hôpital Pitié-Salpêtrière, AP-HP, Paris, France.
³⁴ Department of Hematology, Centre hospitalo-Universitaire, Nantes, France.
³⁵ Department of Hematology, Dijon Bourgogne University Hospital and INSERM UMR 1231, Dijon, France.
³⁶ Research and Clinical Innovation Department, Antoine Lacassagne Cancer Center, Nice, France.
³⁷ Department of Hematology, CHU UCL Namur, Yvoir, Belgium.
³⁸ Université de Lille, Centre Hospitalier Universitaire (CHU) Lille, ULR 7365 - GRITA - Groupe de Recherche sur les Formes Injectables et les Technologies Associées, Lille, France.
³⁹ Department of Hematology, Institut de Cancérologie Strasbourg Europe (ICANS), Strasbourg, France.
⁴⁰ Department of Hematology, Hospices Civils de Lyon, CHU Lyon-Sud, Pierre-Bénite, France.

PMID: 39509848
DOI: 10.1016/j.ejca.2024.115073

Abstract

Classic Hodgkin lymphoma (HL) is a distinct entity among hematological malignancies of B-cell origin. It is characterized by its unique histopathological features and generally favorable prognosis. Over the years, advancements in understanding its pathogenesis, coupled with refined diagnostic and evaluation modalities, as well as therapeutic strategies, have significantly transformed the landscape of HL management. In this article, we present a comprehensive set of recommendations for the management of HL, encompassing various aspects of diagnosis, risk stratification, evaluation, and treatment. These recommendations are based on the latest evidence-based guidelines, expert consensus opinions, and clinical trial data, aiming to provide clinicians with a practical framework for delivering optimal care to patients with HL.

Keywords: Classic Hodgkin lymphoma; Guidelines.

PubMed Disclaimer

Conflict of interest statement

Declaration of Competing Interest CR has received a research grant from Roche and personal fees and non-financial support from Janssen, Roche, Takeda, and Abbvie. ROC has received a research grant from Gilead and Takeda and personal fees and non-financial support from Janssen, Roche, Takeda, Merck/BMS, Abbvie, and Amgen. The other authors declare no competing interests. MA performed scientific and medical consul/ng for Novar/s, Janssen, Kite/Gilead and MSD and received research grants from Mnemo Therapeutics. R.D. reports honoraria from Novar/s and Takeda; and support for attending meetings and/or travel from Sanofi and Kite Pharma / Gilead. GM reports honoraria from Takeda, Bristol Myers Squibb, Gilead Kite, and Abbvie. All remaining authors have declared no conflicts of interest

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- ClinicalKey
- Elsevier Science
Medical
- MedlinePlus Health Information

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Classic Hodgkin Lymphoma: The LYSA pragmatic guidelines

Affiliations

Classic Hodgkin Lymphoma: The LYSA pragmatic guidelines

Authors

Affiliations

Abstract

Conflict of interest statement

Publication types

MeSH terms

LinkOut - more resources

Full Text Sources

Medical